NVP-ADW742 (CAS: 475488-23-4) is a small-molecule inhibitor of insulin-like growth factor receptor-1 (IGF-1R) and insulin receptor (IR) developed by Novartis for the treatment of various cancers, such as breast cancer and lung cancer. IGF-1R and IR are key receptors involved in tumor cell proliferation, survival, and metastasis.
Chemical name: 5-(3-bromoanilino)-7-fluoro-3-[(3-methylpyridin-2-yl)methoxy]quinoline-4-carboxamide
Molecular formula: C24H18BrFN4O2
Formula weight: 483.32 g/mol
CAS No: 475488-23-4
Top ten keywords from Google:
Health benefits of this product: NVP-ADW742 has shown potential in preclinical and clinical studies for the treatment of various cancers, such as breast cancer and lung cancer. It works by inhibiting the activity of IGF-1R and IR, which promote tumor growth and metastasis. By blocking these receptors, NVP-ADW742 can potentially reduce tumor progression and metastasis.
Potential effects: NVP-ADW742 has shown promising anti-tumor activity in preclinical and clinical studies. In particular, it has demonstrated efficacy in reducing tumor growth and inducing remission in breast cancer and lung cancer. It has also shown potential in combination with other anti-cancer agents, such as chemotherapy and radiation therapy. However, more research is needed to determine its full potential and efficacy in different types of tumors.
Product mechanism: NVP-ADW742 works by inhibiting the activity of IGF-1R and IR, which are involved in the regulation of tumor cell proliferation, survival, and metastasis. Overexpression or mutation of these receptors is associated with various cancers, including breast cancer and lung cancer. As a tyrosine kinase inhibitor, NVP-ADW742 binds to the ATP-binding site of IGF-1R and IR, preventing their activation and downstream signaling pathways that promote cancer cell growth and metastasis. By inhibiting IGF-1R and IR, NVP-ADW742 can block tumor progression and metastasis.
Safety: NVP-ADW742 has been evaluated in several preclinical and clinical studies involving hundreds of patients with different types of cancers. Overall, it has been well-tolerated, with manageable side effects. The most common adverse events reported were fatigue, diarrhea, and nausea. More severe side effects, such as liver toxicity and renal impairment, were observed in some patients, but they were rare and usually resolved after dose adjustments or discontinuation.
Side effects: Common side effects of NVP-ADW742 include fatigue, diarrhea, and nausea. These symptoms are usually mild or moderate and can be managed with supportive care or dose modifications. Less common but more severe side effects may include liver toxicity and renal impairment, which may require prompt medical intervention. Patients should be monitored closely for these adverse events and receive appropriate medical intervention if necessary.
Dosing information: The recommended dose of NVP-ADW742 varies depending on the indication and the patient's condition. In clinical trials, doses ranging from 100 to 400 mg/day have been evaluated, either as a single agent or in combination with other drugs. Treatment duration also varies and can range from a few weeks to several months, depending on the response and tolerability. Patients should follow their doctor's instructions regarding dosing, administration, and monitoring.
Conclusion: NVP-ADW742 is a promising small-molecule inhibitor of IGF-1R and IR that has shown potential in preclinical and clinical studies for the treatment of various cancers, such as breast cancer and lung cancer. Its mechanism of action involves blocking key receptors involved in tumor growth and metastasis, leading to reduced tumor progression and metastasis. Although it has been generally well-tolerated, it may cause some side effects that should be monitored closely. Further research is needed to determine its full potential and efficacy in different types of cancers.